Market Overview

Deutsche Bank Reiterates Hold on Abbott Laboratories Following Release of MitraClip FDA Panel Documents

Related ABT
Markets Sell-Off After Malaysian Airline Crash In Ukraine
UPDATE: Morgan Stanley Reiterates On Abbott Laboratories As Growth and Margins Are Set To Continue
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

In a report published Monday, Deutsche Bank analyst Kristen Stewart reiterated a Hold rating and $33.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Stewart noted, “The FDA has released panel documents for MitraClip, which will be evaluated by an FDA Circulatory Systems Devices Panel on March 20. The MitraClip device is a minimally invasive catheter-based device used to treat mitral regurgitation. The device received CE Mark in 2008 with sales annualizing ~$120M and has been pending FDA panel review for several years. We've had low expectations for MitraClip in the US and as such, the panel docs do not change our view on the stock. Maintain Hold.”

Abbott Laboratories closed on Friday at $34.14.

Posted-In: Deutsche BankAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional